Literature DB >> 9059889

Killer cell inhibitory receptors: diversity, specificity, and function.

E O Long1, D N Burshtyn, W P Clark, M Peruzzi, S Rajagopalan, S Rojo, N Wagtmann, C C Winter.   

Abstract

NK cells selectively kill target cells that fail to express self-MHC class I molecules. This selective killing results from a balance between inhibitory NK receptors specific for MHC class I molecules and activating receptors that are still largely unknown. Isolation of molecular clones for the human killer cell inhibitory receptors (KIR) revealed that KIR consist of a family of molecules with Ig ectodomains and cytoplasmic tails of varying length. Soluble complexes of KIR and HLA-C molecules established that KIR recognizes and binds to its ligand as an autonomous receptor. A functional expression system in human NK clones demonstrated that a single KIR can provide both recognition of MHC class I and delivery of a dominant negative signal to the NK cell. Functional evidence has been obtained for a role of the tyrosine phosphatase SHP-1 in KIR-mediated inhibition. The presence of a conserved motif used to recruit and activate SHP-1 in the cytoplasmic tail of KIR and of the mouse Ly-49 inhibitory receptor (otherwise structurally unrelated to KIR) represents an interesting case of evolutionary convergence. Furthermore, the motif led to the identification of other receptors with inhibitory potential, including a type I Ig-like receptor shared by mouse mast cells and NK cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059889     DOI: 10.1111/j.1600-065x.1997.tb00946.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  37 in total

1.  Alloreactivity and association of human natural killer cells with the major histocompatibility complex.

Authors:  E Mavoungou; A Sall; V Poaty-Mavoungou; F S Toure; P Yaba; A Delicat; J Lansoud-Soukate
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 2.  Intraepithelial lymphocytes in celiac disease immunopathology.

Authors:  Valérie Abadie; Valentina Discepolo; Bana Jabri
Journal:  Semin Immunopathol       Date:  2012-06-03       Impact factor: 9.623

3.  Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users.

Authors:  Costin Tomescu; Fuh-Mei Duh; Michael A Lanier; Angela Kapalko; Karam C Mounzer; Maureen P Martin; Mary Carrington; David S Metzger; Luis J Montaner
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

4.  Regulation of ITAM-positive receptors: role of IL-12 and IL-18.

Authors:  John R Ortaldo; Robin Winkler-Pickett; Jon Wigginton; Meagan Horner; Earl W Bere; Anna T Mason; Narayan Bhat; James Cherry; Michael Sanford; Deborah L Hodge; Howard A Young
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation.

Authors:  Costin Tomescu; Jihed Chehimi; Vernon C Maino; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2009-02-23       Impact factor: 4.962

Review 6.  The mother-child union: the case of missing-self and protection of the fetus.

Authors:  W M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).

Authors:  Felix A Deuss; Benjamin S Gully; Jamie Rossjohn; Richard Berry
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

8.  Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.

Authors:  Costin Tomescu; Domenico Mavilio; Luis J Montaner
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

Review 9.  Natural killer cell immune responses.

Authors:  Wayne M Yokoyama
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 10.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.